Cargando…

HSV Recombinant Vectors for Gene Therapy

The very deep knowledge acquired on the genetics and molecular biology of herpes simplex virus (HSV), has allowed the development of potential replication-competent and replication-defective vectors for several applications in human healthcare. These include delivery and expression of human genes to...

Descripción completa

Detalles Bibliográficos
Autores principales: Manservigi, Roberto, Argnani, Rafaela, Marconi, Peggy
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936037/
https://www.ncbi.nlm.nih.gov/pubmed/20835362
http://dx.doi.org/10.2174/1874357901004010123
_version_ 1782186443274190848
author Manservigi, Roberto
Argnani, Rafaela
Marconi, Peggy
author_facet Manservigi, Roberto
Argnani, Rafaela
Marconi, Peggy
author_sort Manservigi, Roberto
collection PubMed
description The very deep knowledge acquired on the genetics and molecular biology of herpes simplex virus (HSV), has allowed the development of potential replication-competent and replication-defective vectors for several applications in human healthcare. These include delivery and expression of human genes to cells of the nervous systems, selective destruction of cancer cells, prophylaxis against infection with HSV or other infectious diseases, and targeted infection to specific tissues or organs. Replication-defective recombinant vectors are non-toxic gene transfer tools that preserve most of the neurotropic features of wild type HSV-1, particularly the ability to express genes after having established latent infections, and are thus proficient candidates for therapeutic gene transfer settings in neurons. A replication-defective HSV vector for the treatment of pain has recently entered in phase 1 clinical trial. Replication-competent (oncolytic) vectors are becoming a suitable and powerful tool to eradicate brain tumours due to their ability to replicate and spread only within the tumour mass, and have reached phase II/III clinical trials in some cases. The progress in understanding the host immune response induced by the vector is also improving the use of HSV as a vaccine vector against both HSV infection and other pathogens. This review briefly summarizes the obstacle encountered in the delivery of HSV vectors and examines the various strategies developed or proposed to overcome such challenges.
format Text
id pubmed-2936037
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-29360372010-09-10 HSV Recombinant Vectors for Gene Therapy Manservigi, Roberto Argnani, Rafaela Marconi, Peggy Open Virol J Article The very deep knowledge acquired on the genetics and molecular biology of herpes simplex virus (HSV), has allowed the development of potential replication-competent and replication-defective vectors for several applications in human healthcare. These include delivery and expression of human genes to cells of the nervous systems, selective destruction of cancer cells, prophylaxis against infection with HSV or other infectious diseases, and targeted infection to specific tissues or organs. Replication-defective recombinant vectors are non-toxic gene transfer tools that preserve most of the neurotropic features of wild type HSV-1, particularly the ability to express genes after having established latent infections, and are thus proficient candidates for therapeutic gene transfer settings in neurons. A replication-defective HSV vector for the treatment of pain has recently entered in phase 1 clinical trial. Replication-competent (oncolytic) vectors are becoming a suitable and powerful tool to eradicate brain tumours due to their ability to replicate and spread only within the tumour mass, and have reached phase II/III clinical trials in some cases. The progress in understanding the host immune response induced by the vector is also improving the use of HSV as a vaccine vector against both HSV infection and other pathogens. This review briefly summarizes the obstacle encountered in the delivery of HSV vectors and examines the various strategies developed or proposed to overcome such challenges. Bentham Open 2010-06-18 /pmc/articles/PMC2936037/ /pubmed/20835362 http://dx.doi.org/10.2174/1874357901004010123 Text en © Manservigi et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Manservigi, Roberto
Argnani, Rafaela
Marconi, Peggy
HSV Recombinant Vectors for Gene Therapy
title HSV Recombinant Vectors for Gene Therapy
title_full HSV Recombinant Vectors for Gene Therapy
title_fullStr HSV Recombinant Vectors for Gene Therapy
title_full_unstemmed HSV Recombinant Vectors for Gene Therapy
title_short HSV Recombinant Vectors for Gene Therapy
title_sort hsv recombinant vectors for gene therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936037/
https://www.ncbi.nlm.nih.gov/pubmed/20835362
http://dx.doi.org/10.2174/1874357901004010123
work_keys_str_mv AT manservigiroberto hsvrecombinantvectorsforgenetherapy
AT argnanirafaela hsvrecombinantvectorsforgenetherapy
AT marconipeggy hsvrecombinantvectorsforgenetherapy